Should I buy or sell Reata Pharmaceuticals stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RETA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RETA, but not buy additional shares or sell existing shares. View RETA analyst ratings or view top-rated stocks .

What is Reata Pharmaceuticals' stock price target for 2024?

12 equities research analysts have issued 12 month price objectives for Reata Pharmaceuticals' stock. Their RETA share price targets range from $115.00 to $173.00. On average, they expect the company's share price to reach $162.44 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View analysts price targets for RETA or view top-rated stocks among Wall Street analysts .

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its earnings results on Monday, November, 8th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.32) by $0.35. The firm earned $7.40 million during the quarter, compared to analyst estimates of $2.07 million. The business's quarterly revenue was up 428.6% on a year-over-year basis. During the same period in the prior year, the business posted ($1.94) earnings per share.

What ETFs hold Reata Pharmaceuticals' stock?

ETFs with the largest weight of Reata Pharmaceuticals (NASDAQ:RETA) stock in their portfolio include Subversive Mental Health ETF (SANE) , iShares U.S. Pharmaceuticals ETF (IHE) , Principal Healthcare Innovators ETF (BTEC) , Invesco DWA SmallCap Momentum ETF (DWAS) , First Trust Small Cap Growth AlphaDEX Fund (FYC) and Invesco Nasdaq Biotechnology ETF (IBBQ) . iShares Biotechnology ETF (IBB) .

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com . Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX) , Precision Drilling (PDS) , First Financial Bankshares (FFIN) , Synlogic (SYBX) , NVIDIA (NVDA) , Basic Energy Services (BAS) , Sarepta Therapeutics (SRPT) , Gilead Sciences (GILD) , Inovio Pharmaceuticals (INO) and Archrock (AROC) .

When did Reata Pharmaceuticals IPO?

Reata Pharmaceuticals (RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

NASDAQ:RETA

Reata Pharmaceuticals (RETA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free RETA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $172.32
▼
$172.46
50-Day Range: $168.70
▼
$172.36
52-Week Range: $21.83
▼
$172.46

Volume: 1.99 million shs
Average Volume: 1.09 million shs
Market Capitalization: $6.58 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $162.44

Stock Analysis

Get Reata Pharmaceuticals alerts:

Reata Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 5.8% Downside
$162.44 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.02) to ($2.71) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.51 out of 5 stars

Medical Sector

871st out of 918 stocks

Pharmaceutical Preparations Industry

393rd out of 417 stocks

1.1

Analyst's Opinion

Consensus Rating
Reata Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 9 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Reata Pharmaceuticals has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for RETA.

0.0

Dividend Strength

Dividend Yield
Reata Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reata Pharmaceuticals does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Reata Pharmaceuticals has received a 78.64% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Reata Pharmaceuticals is -0.75.

N/A

News and Social Media Coverage

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reata Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
26.80% of the stock of Reata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Reata Pharmaceuticals are expected to grow in the coming year, from ($3.02) to ($2.71) per share.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Reata Pharmaceuticals Stock (NASDAQ:RETA)

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

RETA Stock News Headlines

January 25, 2024 | markets.businessinsider.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

December 29, 2023 | msn.com

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

November 14, 2023 | investing.com

Biogen cuts annual profit forecast on higher deal costs (Nov 8)

November 8, 2023 | proactiveinvestors.com

Biogen lowers full-year earnings guidance, 3Q revenue beats expectations

November 8, 2023 | investing.com

Biogen cuts annual profit forecast as higher costs persist

October 1, 2023 | msn.com

Top Growth Stocks for October 2023

September 26, 2023 | finanznachrichten.de

Biogen Inc.: Biogen Completes Acquisition of Reata Pharmaceuticals

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

September 26, 2023 | finance.yahoo.com

Biogen Completes Acquisition of Reata Pharmaceuticals

September 13, 2023 | finance.yahoo.com

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near Future

September 9, 2023 | finance.yahoo.com

Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?

August 28, 2023 | businesswire.com

REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale ...

August 15, 2023 | msn.com

Cantor Fitzgerald Reiterates Reata Pharmaceuticals Inc - (RETA) Neutral Recommendation

August 11, 2023 | benzinga.com

Reata Pharmaceuticals Unusual Options Activity For August 11

August 9, 2023 | markets.businessinsider.com

Reata Pharmaceuticals (RETA) Gets a Hold from Barclays

August 2, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, EQRX, RVMD

August 2, 2023 | msn.com

Reata Pharmaceuticals Inc - (RETA) Price Target Increased by 53.21% to 175.90

July 29, 2023 | msn.com

Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors

July 28, 2023 | investing.com

Biogen agrees to acquire neurological disease specialist Reata Pharmaceuticals at 60% premium

July 28, 2023 | technews.tmcnet.com

RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders

July 28, 2023 | finance.yahoo.com

Biogen to Acquire Reata Pharmaceuticals

July 28, 2023 | marketwatch.com

Reata Pharmaceuticals Shares Soar on Takeover by Biogen >RETA

July 28, 2023 | markets.businessinsider.com

Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?

July 24, 2023 | markets.businessinsider.com

Expert Ratings for Reata Pharmaceuticals

July 6, 2023 | msn.com

TD Cowen starts Reata at outperform, cites sales potential of ataxia drug

June 30, 2023 | nasdaq.com

Ladenburg Thalmann Maintains Reata Pharmaceuticals Inc - (RETA) Buy Recommendation

See More Headlines

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RETA
CUSIP: N/A
CIK: 1358762
Web: www.reatapharma.com
Phone: (972) 865-2219
Fax: N/A
Employees: 321
Year Founded: 2002

Price Target and Rating

Average Stock Price Target: $162.44
High Stock Price Target: $173.00
Low Stock Price Target: $115.00
Potential Upside/Downside: -5.8%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-311,900,000.00
Net Margins: N/A
Pretax Margin: -373.40%
Return on Equity: -922.50%
Return on Assets: -73.39%

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 3.21
Quick Ratio: 3.19

Sales & Book Value

Annual Sales: $23.48 million
Price / Sales: 280.05
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.79) per share
Price / Book: -96.29

Miscellaneous

Outstanding Shares: 38,150,000
Free Float: 27,926,000
Market Cap: $6.58 billion
Optionable: Optionable
Beta: 1.42

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. J. Warren Huff (Age 69)
Chairman, CEO & Sec.
Comp: $1.11M
Mr. Manmeet Singh Soni (Age 45)
COO, CFO & Pres
Comp: $1.02M
Mr. Michael D. Wortley (Age 75)
Exec. VP and Chief Legal & Compliance Officer
Comp: $773.06k
Dr. Colin J. Meyer M.D. (Age 44)
Exec. VP & Chief Innovation Officer
Comp: $842.4k
Ms. Dawn Carter Bir (Age 52)
Exec. VP & Chief Commercial Officer
Comp: $652.39k
Mr. Bhaskar Anand (Age 45)
Sr. VP & Chief Accounting Officer
Dr. W. Christian Wigley Ph.D.
Sr. VP & Chief Scientific Officer
Mr. Steve Harman
Sr. VP & Chief HR Officer
Dr. Samina Khan M.D. (Age 58)
Chief Medical Officer & Sr. VP
Mr. Dakota Gallivan
VP & Chief Healthcare Compliance Officer

Key Competitors

View All Competitors

Insiders

RETA Stock Analysis - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RETA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RETA, but not buy additional shares or sell existing shares.
View RETA analyst ratings or view top-rated stocks.
What is Reata Pharmaceuticals' stock price target for 2024?: 12 equities research analysts have issued 12 month price objectives for Reata Pharmaceuticals' stock. Their RETA share price targets range from $115.00 to $173.00. On average, they expect the company's share price to reach $162.44 in the next twelve months. This suggests that the stock has a possible downside of 5.8%.
View analysts price targets for RETA or view top-rated stocks among Wall Street analysts.
How were Reata Pharmaceuticals' earnings last quarter?: Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its earnings results on Monday, November, 8th. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.32) by $0.35. The firm earned $7.40 million during the quarter, compared to analyst estimates of $2.07 million. The business's quarterly revenue was up 428.6% on a year-over-year basis. During the same period in the prior year, the business posted ($1.94) earnings per share.
What ETFs hold Reata Pharmaceuticals' stock?: ETFs with the largest weight of Reata Pharmaceuticals (NASDAQ:RETA) stock in their portfolio include Subversive Mental Health ETF (SANE), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), Invesco DWA SmallCap Momentum ETF (DWAS), First Trust Small Cap Growth AlphaDEX Fund (FYC) and Invesco Nasdaq Biotechnology ETF (IBBQ).iShares Biotechnology ETF (IBB).

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?: 10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Reata Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).
When did Reata Pharmaceuticals IPO?: Reata Pharmaceuticals (RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

This page (NASDAQ:RETA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Reata Pharmaceuticals (RETA) Stock Price, News & Analysis